Sign In
Buy FBIO
$3.13
-0.160 (-4.86%)
At Close: Jul 31, 2026
Journey Medical Corporation to Present at the Emerging Growth Conference
08:30am, Monday, 18'th Aug 2025
SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical com
Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates
06:56pm, Thursday, 14'th Aug 2025
Fortress Biotech (FBIO) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.73 per share a year ago.
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
04:05pm, Thursday, 14'th Aug 2025
Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right
Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
04:01pm, Tuesday, 12'th Aug 2025
S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in J
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
08:30am, Thursday, 07'th Aug 2025
SCOTTSDALE, Ariz., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical
Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
04:01pm, Tuesday, 05'th Aug 2025
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide
Why Fast-paced Mover Fortress Biotech (FBIO) Is a Great Choice for Value Investors
09:50am, Monday, 14'th Jul 2025
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks tha
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
08:30am, Monday, 14'th Jul 2025
Payer coverage for Emrosi™ now available for 65% of commercial lives, up from 29% in May 2025 Expanding payer coverage supports the adoption of Emrosi as prescription demand continues to increase SC
Journey Medical to Join Russell 2000® and Russell 3000® Indexes
08:30am, Tuesday, 24'th Jun 2025
SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or “our”), a commercial-stage pharmaceutical
Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent of body weight differences when trea
Despite Fast-paced Momentum, Fortress Biotech (FBIO) Is Still a Bargain Stock
09:51am, Thursday, 19'th Jun 2025
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks tha
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
08:30am, Monday, 09'th Jun 2025
National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz.
Fortress Biotech (FBIO) Is Attractively Priced Despite Fast-paced Momentum
09:50am, Tuesday, 03'rd Jun 2025
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks tha
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
10:47am, Friday, 30'th May 2025
Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (c
New Strong Sell Stocks for May 16th
06:51am, Friday, 16'th May 2025
FBIO, AFCG and HRZN have been added to the Zacks Rank #5 (Strong Sell) List on May 16, 2025.
